Loading...

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

BACKGROUND: Pertuzumab disrupts heterodimerization between human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, and HER4. Thus, pertuzumab could result in adverse events similar to those observed with EGFR antagonists, such as diarrhea. We report the inc...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Ann Oncol
Main Authors: Swain, S. M., Schneeweiss, A., Gianni, L., Gao, J. J., Stein, A., Waldron-Lynch, M., Heeson, S., Beattie, M. S., Yoo, B., Cortes, J., Baselga, J.
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2017
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834072/
https://ncbi.nlm.nih.gov/pubmed/28057664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw695
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!